Welcome to our dedicated page for Lexaria Bioscien news (Ticker: LEXXW), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscien stock.
Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) regularly issues news updates that focus on the development and evaluation of its patented DehydraTECH™ oral drug delivery platform. Company press releases highlight progress in human and animal studies, capital raising activities, strategic partnerships, and expansion of its intellectual property portfolio. For followers of LEXXW, this news flow offers insight into how DehydraTECH is being tested and positioned within the pharmaceutical landscape.
A major theme in Lexaria’s recent news is its work with GLP‑1 drugs such as semaglutide, tirzepatide, and liraglutide. The company reports results from multiple human pilot studies and a Phase 1b study in Australia (GLP‑1‑H24‑4), where DehydraTECH‑processed oral formulations are compared against established injectable or oral products. These releases detail safety and tolerability outcomes, reductions in total and gastrointestinal adverse events, and comparative performance on measures like HbA1c, body weight, body composition, and pharmacokinetics.
News items also cover exploratory findings with DehydraTECH‑CBD, including reported blood pressure reductions in a clinical study arm, and pre-clinical work such as a fluorescently tagged semaglutide rodent biodistribution study. Beyond R&D, Lexaria’s announcements describe registered direct offerings on Nasdaq, concurrent warrant placements, and the intended use of proceeds to fund research, working capital, and general corporate purposes.
Additional updates include the extension of a Material Transfer Agreement with a pharmaceutical company to evaluate DehydraTECH, the engagement of a global life science business development advisory firm, and the issuance of new patents in areas such as diabetes, epilepsy, and antiviral treatments. Investors and observers monitoring LEXXW news can use these releases to track Lexaria’s clinical progress, partnering discussions, financing activities, and the evolution of its DehydraTECH-focused strategy over time.
Lexaria Bioscience Corp. has selected InClin, a California-based CRO, to manage its upcoming Phase 1b hypertension study, titled HYPER-H23-1, evaluating the safety and efficacy of its patented DehydraTECH-CBD. The study aims to assess the treatment on 120 patients with Stage 1 and Stage 2 hypertension, following successful FDA pre-IND meeting outcomes. Lexaria plans to file its IND application this summer, anticipating FDA authorization within 60 days. Previous studies indicated that DehydraTECH-CBD significantly reduced blood pressure with no serious adverse events, setting it apart from other CBD formulations. The company is also working on the necessary stability testing for its drug product, which is crucial for the IND submission.
Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) has announced the receipt of four new patents, enhancing its intellectual property portfolio globally. In Japan, a patent for Stable Ready-to-Drink Beverage Compositions marks the 5th awarded in the country; in Australia, a patent for Enhanced Delivery of Antiviral Agents becomes the 10th. Canada has allowed a patent for Nicotine Compounds, and the USA has granted a patent for Treating Hypertension, crucial for future FDA applications. These patents underscore Lexaria's commitment to expanding its DehydraTECH technology, vital in the lucrative cardiovascular drugs market projected to grow from US$146.5 billion in 2022 to $173.5 billion by 2026. With these additions, Lexaria's patent portfolio increases to 32 granted patents worldwide.
Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) has completed its diabetes study DIAB-A22-1, demonstrating significant positive effects of DehydraTECH-CBD on obese diabetic rats. Key outcomes include:
- Approximately 7% weight loss over 8 weeks, with treated animals losing weight while untreated animals gained weight.
- Improved metabolic function indicated by stable food and water intake despite weight loss.
- Significant reductions in triglyceride levels, with the lower dose achieving over 25% reduction compared to untreated rats.
- Potential enhancement of activity levels at lower doses of DehydraTECH-CBD.
These findings encourage further investigation into using DehydraTECH-CBD for diabetes treatment.
Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW) has announced significant results from its clinical study HYPER-H21-4, which assessed the blood pressure-lowering effects of its DehydraTECH-processed CBD capsules. The study demonstrated a substantial and sustained reduction in blood pressure over five weeks, with no serious adverse events reported. Key findings include a 28.5% decrease in serum catestatin levels and a statistically significant drop in mean arterial pressure. These results suggest that Lexaria's CBD formulation may offer a novel therapeutic approach for managing hypertension, particularly for patients resistant to standard treatments.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has appointed Julian Gangolli, the former President of GW Pharmaceuticals USA, as a Strategic Advisor. Gangolli, known for overseeing the FDA approval of Epidiolex, aims to assist Lexaria in commercializing its DehydraTECH technology. The company is focusing on executing its technology portfolio in 2023. Gangolli's background includes leadership roles at Allergan, further strengthening Lexaria's team. He will receive stock options for 5,000 shares at an exercise price of $2.73. Lexaria's DehydraTECH enhances drug absorption and has 28 patents granted worldwide.
Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) released its annual update, emphasizing resilience amid economic challenges. Despite market declines and rising inflation, Lexaria maintained its workforce and effectively managed expenses, hitting budget targets for two consecutive years. The company is progressing in discussions with several multi-billion dollar firms to license its DehydraTECH technology. Lexaria's 2022 successes include a pre-IND FDA meeting for its hypertension drug and significant institutional investment increases. Looking ahead, Lexaria aims to commercialize DehydraTECH-CBD through FDA trials and strategic partnerships in 2023.
Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) announced it received its first granted patent in Canada, marking its 28th globally. The Canadian Patent #3,093,414 pertains to transdermal and dermal delivery methods for cannabinoids, including CBD and THC. This advance opens new pharmaceutical applications and enhances skin-penetration of active ingredients. Past studies demonstrated a nearly 1,900% increase in CBD permeability using Lexaria's technology. The patent underscores Lexaria's innovation in drug delivery and strengthens its intellectual property portfolio.
Lexaria Bioscience Corp. has announced significant results from its clinical hypertension study, HYPER-H21-4. The study showed that Lexaria's DehydraTECH-CBD achieved a 45.8% higher average blood plasma CBD level (33.3 ng/mL) than published pharmaceutical-grade CBD comparators at a lower dosage (3.38 mg/kg). At the highest tested dose of 4.46 mg/kg, this level rose to 53.7 ng/mL, indicating a 141% improvement over previous formulations. CEO Chris Bunka emphasized the importance of these results for patient health outcomes and Lexaria's pursuit of FDA registration for DehydraTECH-CBD.
Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) has initiated dosing in its human clinical study, NIC-H22-1, aimed at evaluating DehydraTECH-nicotine pouches against leading brands ON! and Zyn. This randomized, double-blinded study includes 36 participants and will assess nicotine absorption and subjective experiences. Fully funded internally, the study taps into the rapidly growing oral nicotine pouch market, projected to reach $21.84 billion by 2027. Lexaria recently secured its first patent for DehydraTECH in nicotine delivery, promising competitive advantages in this space.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) announces that its patented DehydraTECH-CBD has shown enhanced effectiveness compared to Epidiolex in animal studies. The initial pilot study indicated that at lower doses of 50 mg/kg and 75 mg/kg, DehydraTECH-CBD was more effective than Epidiolex in reducing seizure activity. The secondary study revealed faster onset of action for DehydraTECH-CBD, with effective results observed at 30 and 60 minutes post-dosing. Lexaria plans to continue optimizing DehydraTECH-CBD formulations and conducting further studies to establish definitive dosing metrics.